News & Updates
Filter by Specialty:
Metformin, ivermectin, fluvoxamine OUT for severe COVID-19 prevention?
The use of metformin, fluvoxamine, or ivermectin in an outpatient setting did not appear to prevent progression to severe COVID-19, according to results of the phase III COVID-OUT trial.
Metformin, ivermectin, fluvoxamine OUT for severe COVID-19 prevention?
11 Oct 2022
Telmisartan does not deliver in peripheral arterial disease
Treatment with the angiotensin receptor blocker telmisartan does not appear to confer improvements on walking performance in patients with lower extremity peripheral artery disease (PAD), according to the TELEX trial.
Telmisartan does not deliver in peripheral arterial disease
11 Oct 2022
Osimertinib plus selumetinib shows promise in advanced NSCLC
The combination of osimertinib plus selumetinib exhibits antitumour activity in patients with MET-negative, EGFRm advanced nonsmall cell lung cancer (NSCLC), with the safety profile consistent with the reported safety data for the drugs, according to data from the small open-label, phase Ib study.
Osimertinib plus selumetinib shows promise in advanced NSCLC
11 Oct 2022
Cefepime/enmetazobactam effective for suspected gram-negative complicated UTI
Patients with complicated urinary tract infection (UTI) or acute pyelonephritis caused by gram-negative pathogens may fare better with cefepime/enmetazobactam than with piperacillin/tazobactam, as the former is associated with a greater likelihood of achieving treatment success, according to the results of a phase III trial.
Cefepime/enmetazobactam effective for suspected gram-negative complicated UTI
11 Oct 2022
Dimethyl fumarate bests interferon β-1a in paediatric-onset multiple sclerosis
The use of dimethyl fumarate (DMF) in the treatment of children with paediatric-onset multiple sclerosis (POMS) appears to produce more favourable effects than interferon β-1a (IFNβ-1a), with those on DMF being less likely to have new or newly enlarging lesions and experience relapse, according to data from the open-label CONNECT study.
Dimethyl fumarate bests interferon β-1a in paediatric-onset multiple sclerosis
10 Oct 2022
Bronchodilators ineffective in symptomatic, tobacco-exposed patients without COPD
Bronchodilators, used in the treatment of chronic obstructive pulmonary disease (COPD), did not appear to benefit individuals with a history of smoking and respiratory symptoms who did not have airflow obstruction, results of the US-based RETHINC* study showed.
